Your browser doesn't support javascript.
loading
Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial.
Nicholls, Stephen J; Nissen, Steven E; Fleming, Cynthia; Urva, Shweta; Suico, Jeffrey; Berg, Paul H; Linnebjerg, Helle; Ruotolo, Giacomo; Turner, P Kellie; Michael, Laura F.
Affiliation
  • Nicholls SJ; Victorian Heart Institute, Monash University, Clayton, Victoria, Australia.
  • Nissen SE; Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, Cleveland, Ohio.
  • Fleming C; Eli Lilly and Company, Indianapolis, Indiana.
  • Urva S; Eli Lilly and Company, Indianapolis, Indiana.
  • Suico J; Eli Lilly and Company, Indianapolis, Indiana.
  • Berg PH; Eli Lilly and Company, Indianapolis, Indiana.
  • Linnebjerg H; Eli Lilly and Company, Indianapolis, Indiana.
  • Ruotolo G; Eli Lilly and Company, Indianapolis, Indiana.
  • Turner PK; Eli Lilly and Company, Indianapolis, Indiana.
  • Michael LF; Eli Lilly and Company, Indianapolis, Indiana.
JAMA ; 330(11): 1042-1053, 2023 09 19.
Article in En | MEDLINE | ID: mdl-37638695
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Agents / Lipoprotein(a) / Hypolipidemic Agents Type of study: Clinical_trials Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: En Journal: JAMA Year: 2023 Type: Article Affiliation country: Australia
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Agents / Lipoprotein(a) / Hypolipidemic Agents Type of study: Clinical_trials Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: En Journal: JAMA Year: 2023 Type: Article Affiliation country: Australia